On October 20, 2021 Atlas Corp. ("Atlas") (NYSE: ATCO) reported its financial results for the quarter ended September 30, 2021, after the market close on Monday, November 8, 2021 (Press release, Atlas Therapeutics, OCT 20, 2021, View Source [SID1234591614]). Atlas plans to host a conference call for all shareholders and interested parties at 8:30 a.m. Eastern Time (ET) on Tuesday, November 9, 2021, to discuss the results.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call and Webcast Information:

Conference ID:

3042969

To access the live webcast of the conference call, go to atlascorporation.com and click on "Investor Relations" then "Events & Presentations" for the link. The webcast will be archived on the website for one year.

A replay will be available approximately two hours following the conclusion of the call and accessible until November 23, 2021. The replay telephone numbers are as follows: US/Canada +1 (855) 859-2056 or +1 (800) 585-8367 and International +1 (404) 537-3406, and the replay passcode is: 3042969.

On October 20, 2021 BeyondSpring Pharmaceuticals (the "Company" or "BeyondSpring") (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeutics, reported the presentation of preclinical data in patient-derived cancer models supporting the use of plinabulin in small cell lung cancer (SCLC) at the 2021 AACR (Free AACR Whitepaper)-NCI-EORTC Virtual AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper), held October 7-10, 2021 (Press release, BeyondSpring Pharmaceuticals, OCT 20, 2021, View Source;utm_medium=rss&utm_campaign=beyondspring-pharmaceuticals-announces-new-patient-derived-cancer-model-data-for-plinabulin-monotherpy-at-the-aacr-nci-eortc-virtual-international-conference-to-further-support-the-positive-clinical-d [SID1234591579]). Plinabulin is a selective immunomodulating microtubule-binding agent (SIMBA), which induces dendritic cell maturation for durable anti-cancer benefit, and selectively induces certain types of cancer cell apoptosis, both through immune defense protein GEF-H1 release and activation. This study demonstrates plinabulin’s direct single agent anti-cancer tumor effects in patient-derived models of SCLC and additional cancer types, including glioblastoma multiforme, bladder cancer, gastric cancer, sarcoma and triple-negative breast cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The positive patient-derived (PDX) preclinical data increases our confidence in pursuing SCLC as an indication for plinabulin, which has shown high response rate data in human studies. This is supplemental to the maturation of dendritic cells in the cancer immune system and the induction of downstream mechanisms in specific cancer cell types," said Dr. Kenneth Lloyd, chief scientific officer of BeyondSpring. "The fact that plinabulin has already been associated with tumor responses in SCLC patients in a Phase 1 study presented at the 2021 ASCO (Free ASCO Whitepaper) Annual Meeting is a good indication that these patient-derived models are predictive. The preclinical data presented here supports our intended strategy for developing an option for cancer patients by combining plinabulin and checkpoint inhibitors in SCLC."

The study was intended to screen cancer cells for susceptibility to plinabulin. For this purpose, PDX models of cancer established from patient tumor biopsies were used in a manner that results in minimal chance for changes in cancer cell genetics, and hence, these models are considered more predictive of clinical response than common cancer models. Eighty PDX three-dimensional culture models were tested. Data showed that the cancer types most sensitive to plinabulin were:

SCLC (mean absolute IC70 = 35 nM; n = 7)
Bladder cancer (mean absolute IC70 = 38 nM; n = 9)
Soft tissue sarcoma (mean absolute IC70 = 57 nM; n = 10)
Dr. Lan Huang, BeyondSpring’s co-founder, CEO and chairwoman concluded, "We have been developing plinabulin in multiple cancer indications, based on the effects of plinabulin on dendritic cells and macrophages. Plinabulin’s anti-cancer effect is supported by the positive Phase 3 DUBLIN-3 non-small cell lung cancer study with evidence of the extension of overall survival. Plinabulin has also shown efficacy in preventing chemotherapy-induced neutropenia, which has received Breakthrough Designation and Priority Review from the U.S. FDA. Plinabulin’s single agent anti-cancer activity in PDX SCLC models and the relevant positive immuno-oncology combo preliminary clinical data in SCLC could potentially expand plinabulin’s cancer indications. We look forward to continuing to expand these anti-cancer indications in the clinic and to validate plinabulin as a ‘pipeline in a drug.’"

About Plinabulin

Plinabulin, BeyondSpring’s lead asset, is a selective immunomodulating microtubule-binding agent (SIMBA), which is a potent antigen presenting cell (APC) inducer. It is a novel, intravenous infused, patent-protected, NDA stage asset for CIN prevention and a Phase 3 anti-cancer candidate for non-small cell lung cancer (NSCLC). Plinabulin triggers the release of the immune defense protein, GEF-H1, which leads to two distinct effects: first is a durable anticancer benefit due to the maturation of dendritic cells resulting in the activation of tumor antigen-specific T-cells to target cancer cells, and the second is early-onset of action in CIN prevention after chemotherapy by boosting the number of hematopoietic stem/progenitor cells (HSPCs). It is being developed as a "pipeline in a drug" in multiple cancer indications.

On October 20, 2021 Semmelweis University reported that it has improved its position from the 70th rank since last year and is now ranked 33rd among higher education institutes, according to the Times Higher Education (THE) Emerging Economies Rankings (Press release, Semmelweis University, OCT 20, 2021, View Source [SID1234591597]).

The Times Higher Education Emerging University Ranking use 13 calibrated performance indicators to reflect the characteristics of the emerging economy universities. Semmelweis University has once again climbed the ranking and became the best educational institute in Hungary, moving from 70th to the 33th place of the world’s top universities.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Among the other Hungarian universities on the list, Eötvös Loránd University was ranked 150th, University of Debrecen 191th. As for other universities it looks as follows: University of Pécs and University of Szeged (201-250th). Óbuda University, Budapest University of Technology and Economics, Corvinus University of Budapest, Hungarian University of Agriculture and Life Sciences were ranked 401-500th. University of Miskolc finished 501+ on the list.

China continues to dominate the Emerging Economies rankings occupying the top three positions (Beijing University, Tsinghua University and Zhejiang University) of the table.

On October 20, 2021 NextEra Energy, Inc. (NYSE: NEE) reported that has posted its third-quarter 2021 financial results in a news release available on the company’s website by accessing the following link: www.NextEraEnergy.com/FinancialResults (Press release, Nextera, OCT 20, 2021, View Source [SID1234591615]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jim Robo, chairman and chief executive officer of NextEra Energy, Rebecca Kujawa, executive vice president, finance and chief financial officer of NextEra Energy, and other members of the company’s senior management team will discuss the company’s third-quarter 2021 financial results during an investor presentation to be webcast live, beginning at 9 a.m. ET today. The listen-only webcast will be available on NextEra Energy’s website by accessing the following link: www.NextEraEnergy.com/FinancialResults. Also discussed during the investor presentation will be financial results for NextEra Energy Partners, LP (NYSE: NEP). A replay will be available for 90 days by accessing the same link as listed above.

On October 20, 2021 OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body’s immune system to target and attack cancer, reported that Chris Twitty, Ph.D., Chief Scientific Officer, will be stepping down to pursue a new opportunity with a private oncology company (Press release, OncoSec Medical, OCT 20, 2021, View Source [SID1234591668]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Margaret Dalesandro, Ph.D., Chair of the Board of Directors and Member of the Leadership Committee of OncoSec, remarked, "On behalf of the Board of Directors and the other members of the Leadership Committee, we are grateful to Dr. Twitty for leading OncoSec’s R&D team over the last five years and we thank him for his contributions to our significant progress towards bringing TAVO to patients."

Sandra Aung, Ph.D., Chief Clinical Development Officer, added, "We continue to be encouraged with the maturing data from the KEYNOTE-695 study and look forward to engaging with the health authorities on what we believe is an effective therapy for these patients with no standard of care options."

The formal analysis of KEYNOTE-695 and top-line results of the primary endpoint, Overall Response Rate (ORR) by blinded independent central review (BICR) based on RECIST, will be announced in the first quarter of 2022.

TAVO updated data from the KEYNOTE-695 clinical trial will be made available at 7am EST on Friday, November 12, 2021, in a poster presentation at The Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s (SITC) (Free SITC Whitepaper) 36th Annual Meeting in Washington D.C. The SITC (Free SITC Whitepaper) poster presentation is # 383, entitled: ‘Durable responses with intratumoral electroporation of plasmid interleukin 12 plus pembrolizumab in patients with advanced melanoma progressing on an anti-PD-1 antibody: updated data from Keynote 695.’ OncoSec will make the poster presentation available on its website following publication at SITC (Free SITC Whitepaper) 2021 and will host a SITC (Free SITC Whitepaper) symposium KOL webinar on November 12 at 7am EST for SITC (Free SITC Whitepaper) attendees and investors. Please click here to register for the webinar.

Dr. Herbert Kim Lyerly, Duke University School of Medicine, OncoSec Board of Directors and Member of the Leadership Committee, added, "As an oncologist focused on intra-tumoral cytokine immunotherapies, TAVO is an active drug with a remarkable safety profile, which will serve a PD-1 refractory patient population for whom there are no approved therapies. We are excited to update the community at SITC (Free SITC Whitepaper) 2021."

There will also be updated TAVO data from the ongoing KEYNOTE-890 clinical trial at the 2021 San Antonio Breast Cancer Symposium (SABCS), December 7-10, 2021, in a poster presentation abstract #2196, entitled: ‘Trial in progress: Phase 2 study of intratumoral plasmid interleukin-12 (tavokinogene telseplasmid; TAVO) plus electroporation in combination with pembrolizumab with or without chemotherapy in patients with inoperable locally advanced or metastatic triple-negative breast cancer (KEYNOTE-890/OMS-I141).’ OncoSec will make the poster available on its website following publication at SABCS 2021.

Lastly, regarding the CEO search, the Leadership Committee continues to meet with high quality candidates and expects to name a new CEO in the near-term.